Wednesday, February 19, 2025
12:00PM – 1:00PM ET
Please note this virtual program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM CHAIR & FACULTY
 |
John L. Marshall, MD Director, The Ruesch Center for the Cure of GI Cancers Frederick P. Smith Endowed Chair Chief Medical Officer, Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington, DC |
PROGRAM OVERVIEW
This virtually live Grand Rounds program is focused on advanced, HER2-expressing gastric cancer (GC) or gastroesophageal junction (GEJ) cancers. It will update you on best practices related to HER2 expression testing in this setting, provide a critical review of relevant clinical trial findings, and offer practical guidance on multidisciplinary monitoring and management of treatment-related adverse events in patients receiving a HER2-directed therapy for GC or GEJ cancer. This interactive program combines didactic instruction with case-based discussions and animations.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community medical oncologists and multidisciplinary team members involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Discuss current best practices informing the assessment of HER2 expression in patients with advanced gastric or gastroesophageal junction (GEJ) cancers
- Analyze clinical data informing the use of HER2-directed antibody-drug conjugate therapy in the management of advanced gastric and GEJ cancers
- Review best practices in appropriate monitoring and mitigation of potential adverse events associated with HER2-targeted antibody-drug conjugate therapies, including interstitial lung disease and pneumonitis
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
